Cyclerion Therapeutics, Inc. (CYCN): Nasdaq/NYSE listing notice — Cyclerion gets 180-day bid price extension; transfers to Nasdaq Capital Market

Cyclerion Therapeutics, Inc.

Nasdaq granted extension to May 29, 2023 to regain $1.00 minimum bid price compliance.
Company transferred from Nasdaq Global Market to Capital Market on Nov 25, 2022.
Bid price below $1.00 for 30 consecutive business days; needs 10 consecutive days at $1.00+.
If not cured by May 29, 2023, common stock will be delisted (subject to appeal).
Company intends to cure deficiency via reverse stock split, if necessary.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cyclerion Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Extended Compliance Date, the Staff will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the Staff’s delisting determination to a Na

View on SEC.gov

Browse all listing & compliance notices →

Cyclerion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-025791

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.